Related Experiment Videos
Antithrombotic and thrombolytic therapy for ischemic stroke.
1Department of Neurology, Memorial Health, University of Massachussetts Medical School, Worcester, Massachussetts.
Journal of Thrombosis and Thrombolysis
|June 12, 1999
Summary
Aspirin and dipyridamole help prevent ischemic stroke. Thrombolytic therapy with rt-PA shows promise but carries bleeding risks, necessitating careful patient selection and further research for broader application.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Antithrombotic therapy is crucial for preventing ischemic cerebrovascular disease.
- Aspirin offers modest risk reduction for subsequent ischemic stroke.
- Combination therapy with dipyridamole may enhance aspirin's benefits.
Purpose of the Study:
- To review current antithrombotic and thrombolytic therapies for ischemic stroke.
- To evaluate the efficacy and risks of various treatment options.
- To anticipate future advancements in stroke prevention and treatment.
Main Methods:
- Review of existing literature on antithrombotic agents like aspirin, dipyridamole, and ticlopidine.
- Analysis of the role of anticoagulant therapies (heparin, low-molecular-weight heparin).
- Evaluation of thrombolytic therapy, specifically rt-PA, for acute ischemic stroke.
Main Results:
- Aspirin provides modest stroke risk reduction; dipyridamole may augment this.
- Ticlopidine offers limited additional benefit with increased side effects and cost.
- Heparin therapies are generally not recommended due to bleeding risks, except in specific cases.
- Recombinant tissue plasminogen activator (rt-PA) improves outcomes within 3 hours but has a narrow risk-benefit ratio due to intracerebral hemorrhage risk.
Conclusions:
- Early initiation of antithrombotic treatment is supported.
- Further research is needed to optimize rt-PA use, including patient selection and extending the treatment window.
- Anticipate significant future advancements in antithrombotic and thrombolytic therapies for ischemic stroke.